Clinical Capital Conversations

FemTech is often framed as a market trend. In this episode of “Clinical Capital Conversations”, Dr. Peter M. Kovacs explains why it is actually a long-overdue clinical correction. Together with Roswitha Verwer, Founder and CEO of “YON E”, and Muskaan Bhan, Chief Clinical Officer, this conversation explores why women were historically excluded from clinical trials, how biased data still shape healt...

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs sits down with Roswitha Verwer (YONE) and Karoly Szanto to unpack what most investors miss in early-stage health innovation: execution is the moat. YONE delivered the majority of a 12-month roadmap in 6 months. We break down how it happened, what systems made it possible, and why femtech fundraising is still biased even when th...

This is a continuation of our main conversation on what it takes to turn medical innovation into scalable impact. In this episode, Dr. Peter M. Kovacs sits down with Károly Szántó and Thijmen Meijer to unpack the co-investor question that determines everything in biotech and medtech. If you are building or funding early-stage life sciences, this is the uncomfortable truth: the cap table is a gover...

Europe has elite science. Asia has a capital. So why do so many European university spinouts never reach venture readiness or exits? In this episode, Dr. Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer about the real gaps that block deep tech startups, especially in Central and Eastern Europe, and what a modern support model looks like. What we cover: Why most spinouts never become VC...

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs speaks with Károly Szántó about venture studios, calculated risk, and what it really takes to turn promising innovation into execution. We cover: How a non-linear career becomes a competitive advantage Why focus beats speed in early-stage venture building The difference between high risk and calculated risk What university spin...

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Michaela Hrdlickova about Age Management and why workforce execution risk is one of the most overlooked variables in healthcare investing. We explore how work ability is measured, why leadership quality drives performance, and how investors can protect long-duration returns by treating human capita...

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Ales Vavra, a former hedge fund manager known for exposing weaknesses in overhyped biotech companies. Together, they explore what investors often misunderstand about biotech risk, why due diligence fails, how AI is reshaping investment analysis, and the mindset required to survive the volatility of...

AI memory therapy is no longer a concept. It is here, clinically validated, and already helping dementia patients feel less lonely and more connected. In this episode of Clinical Capital Conversations, Peter M. Kovacs speaks with Kompanion Care founder Peter Markus about Lilia, an AI-powered therapeutic platform that combines reminiscence therapy, family-generated memories, and digital biomarkers...

Inside Europe, a new type of hospital is emerging. In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter sit down with Antonín Hlavinka, the innovation and digitalization lead at University Hospital Olomouc. Together, explore how one of the largest hospitals in the Czech Republic built a functioning AI ecosystem that is delivering measurable clinical impact toda...

Can artificial intelligence bring us closer instead of pulling us apart? In this episode of Clinical Capital Conversations , Dr. Peter M. Kovacs and Pavlina Walter speak with Vassili Le Moigne , founder of InTouch , about how AI voice technology is transforming elder care across 89 countries. Together, they explore how scalable empathy, data ethics, and thoughtful design can redefine how we care f...

Biologics are transforming medicine, but who’s enabling that transformation behind the scenes? In this episode, I sit down with Jiri Raska , Chief Commercial Officer at Quinta Analytica , and Pavlina Walter , to discuss: Why biologics and biosimilars are now the fastest-growing segment in pharma How CROs are evolving from vendors to strategic partners What small biotechs need most to reach clinica...

In this episode of Clinical Capital Conversations , I sat down with Pavlina Walter and our guest Jiri Pavlíček , a mentor, entrepreneur, and one of Central Europe’s most respected MedTech leaders. Together, we explored everything from the European MedTech landscape to AI-driven diagnostics , MDR regulation , and the importance of risk-taking culture .  From navigating post-Communist transitions to...

In this episode, Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer , co-founders of Uniprisma , about how Central Europe’s startup scene is maturing from ideas to execution. They discuss founder psychology, team readiness, ego management, and why venture studios are redefining early-stage investment across Europe. Chapters 00:00  Introduction and context 01:10  What Uniprisma is and how...

In this episode, Peter M. Kovacs speaks with Roswitha Verwer and Dr. Muskaan Bhan, the founders of YON E Health, about transforming personal trauma into global innovation. They discuss the journey from idea to clinical-grade Femtech, data ethics, diversity in research, and why women’s health is the next major frontier for investors and operators alike. Chapters 00:00  Introduction and context 01:1...

What will decide the future of AI in Europe: ethics, bureaucracy, or competitiveness? In this episode, I sit down with Jan Kavalírek, Deputy Minister of Industry and Trade and Government Envoy for AI in the Czech Republic, together with Pavlina Walter, to discuss: Why Czechia was the first EU country to propose AI simplification. How regulation can protect safety without paralysing innovation. Wha...

Who We Are: PMK Group and Our Mission in Biotech | Clinical Capital Conversations Biotech often fails for the wrong reasons. Nearly 60% of clinical trial failures are due to technical execution, not the science itself. In this episode, Dr. Peter M. Kovacs explains why he founded PMK Group, a firm that combines capital with clinical and regulatory expertise to reduce technical failures and accelera...

What does real AI adoption in healthcare look like when you leave the hype behind? In this Prague Episode, I speak with Lukas Benzel, Managing Director of the Czech Association of Artificial Intelligence, and Pavlina Walter. We cover hospital adoption, the shift from sick care to prevention, the role of AI in clinical trials, Europe’s strategic approach, and why Singapore’s model is significant. P...

In this episode, Dr. Peter M. Kovacs shares the story of how a study trip in 2018 transformed his life. Within weeks, he decided to relocate his family to Singapore, a country that would become both his home and the strategic hub for his global healthcare and investment ventures. Why Singapore? A clean, safe, efficient environment A business, biotech, and financial hub Access to Asia’s fast-growin...